Association between CHIP and hs-CRP at study entry (multivariate analysis)
| . | All patients (N = 1887) . | Without baseline CAD (n = 528) . | With baseline CAD (n = 1359) . | |||
|---|---|---|---|---|---|---|
| . | CHIP+ . | CHIP− . | CHIP+ . | CHIP− . | CHIP+ . | CHIP− . |
| Any mutations | ||||||
| n | 427 | 1460 | 134 | 394 | 293 | 1066 |
| hs-CRP GM (IQR), mg/L | 1.85 (0.81-3.77) | 1.5 (0.71-3.00) | 1.86 (0.83-3.82) | 1.51 (0.77-3.02) | 1.84 (0.81-3.72) | 1.49 (0.69-3.01) |
| Back-transformed β (95% CI)* | 1.21 (1.08-1.36) | 1.15 (0.94-1.40) | 1.22 (1.06-1.41) | |||
| % difference | 21 | 15 | 22 | |||
| P* | .001 | .178 | .005 | |||
| DNMT3A | ||||||
| n | 218 | 1669 | 66 | 462 | 152 | 1207 |
| hs-CRP GM (IQR), mg/L | 1.82 (0.80-3.79) | 1.54 (0.73-1.43) | 1.91 (0.81-4.72) | 1.55 (0.77-3.10) | 1.79 (0.78-3.66) | 1.54 (0.71-3.13) |
| Back-transformed β (95% CI)* | 1.17 (1.01-1.36) | 1.23 (0.95-1.59) | 1.15 (0.95-1.38) | |||
| % difference | 17 | 23 | 15 | |||
| P* | .04 | .125 | .148 | |||
| TET2 | ||||||
| n | 115 | 1772 | 48 | 480 | 67 | 1292 |
| hs-CRP GM (IQR), mg/L | 1.78 (0.81-3.46) | 1.56 (0.73-3.19) | 1.77 (0.82-2.77) | 1.58 (0.77-3.27) | 1.79 (0.76-4.01) | 1.55 (0.71-3.17) |
| Back-transformed β (95% CI)* | 1.13 (0.92-1.38) | 0.92 (0.68-1.24) | 1.24 (0.94-1.62) | |||
| % difference | 13 | −8 | 24 | |||
| P* | .253 | .585 | .128 | |||
| ASXL1 | ||||||
| n | 52 | 1835 | 14 | 514 | 38 | 1321 |
| hs-CRP GM (IQR), mg/L | 1.93 (0.88-3.64) | 1.56 (0.73-3.19) | 1.77 (0.96-2.45) | 1.59 (0.77-3.27) | 1.99 (0.83-4.25) | 1.55 (0.71-3.17) |
| Back-transformed β (95% CI)* | 1.26 (0.94-1.69) | 1.09 (0.64-1.86) | 1.31 (0.92-1.87) | |||
| % difference | 26 | 9 | 31 | |||
| P | .128 | .751 | .138 | |||
| PPM1D | ||||||
| n | 38 | 1849 | 9 | 519 | 29 | 1330 |
| hs-CRP GM (IQR), mg/L | 1.64 (0.67-3.43) | 1.57 (0.74-3.19) | 1.84 (0.60-5.09) | 1.59 (0.78-3.23) | 1.59 (0.74-3.28) | 1.56 (0.71-3.18) |
| Back-transformed β (95% CI)* | 0.98 (0.69-1.39) | 1.14 (0.59-2.20) | 0.95 (0.63-1.43) | |||
| % difference | −2 | 14 | −5 | |||
| P | .909 | .705 | .805 | |||
| . | All patients (N = 1887) . | Without baseline CAD (n = 528) . | With baseline CAD (n = 1359) . | |||
|---|---|---|---|---|---|---|
| . | CHIP+ . | CHIP− . | CHIP+ . | CHIP− . | CHIP+ . | CHIP− . |
| Any mutations | ||||||
| n | 427 | 1460 | 134 | 394 | 293 | 1066 |
| hs-CRP GM (IQR), mg/L | 1.85 (0.81-3.77) | 1.5 (0.71-3.00) | 1.86 (0.83-3.82) | 1.51 (0.77-3.02) | 1.84 (0.81-3.72) | 1.49 (0.69-3.01) |
| Back-transformed β (95% CI)* | 1.21 (1.08-1.36) | 1.15 (0.94-1.40) | 1.22 (1.06-1.41) | |||
| % difference | 21 | 15 | 22 | |||
| P* | .001 | .178 | .005 | |||
| DNMT3A | ||||||
| n | 218 | 1669 | 66 | 462 | 152 | 1207 |
| hs-CRP GM (IQR), mg/L | 1.82 (0.80-3.79) | 1.54 (0.73-1.43) | 1.91 (0.81-4.72) | 1.55 (0.77-3.10) | 1.79 (0.78-3.66) | 1.54 (0.71-3.13) |
| Back-transformed β (95% CI)* | 1.17 (1.01-1.36) | 1.23 (0.95-1.59) | 1.15 (0.95-1.38) | |||
| % difference | 17 | 23 | 15 | |||
| P* | .04 | .125 | .148 | |||
| TET2 | ||||||
| n | 115 | 1772 | 48 | 480 | 67 | 1292 |
| hs-CRP GM (IQR), mg/L | 1.78 (0.81-3.46) | 1.56 (0.73-3.19) | 1.77 (0.82-2.77) | 1.58 (0.77-3.27) | 1.79 (0.76-4.01) | 1.55 (0.71-3.17) |
| Back-transformed β (95% CI)* | 1.13 (0.92-1.38) | 0.92 (0.68-1.24) | 1.24 (0.94-1.62) | |||
| % difference | 13 | −8 | 24 | |||
| P* | .253 | .585 | .128 | |||
| ASXL1 | ||||||
| n | 52 | 1835 | 14 | 514 | 38 | 1321 |
| hs-CRP GM (IQR), mg/L | 1.93 (0.88-3.64) | 1.56 (0.73-3.19) | 1.77 (0.96-2.45) | 1.59 (0.77-3.27) | 1.99 (0.83-4.25) | 1.55 (0.71-3.17) |
| Back-transformed β (95% CI)* | 1.26 (0.94-1.69) | 1.09 (0.64-1.86) | 1.31 (0.92-1.87) | |||
| % difference | 26 | 9 | 31 | |||
| P | .128 | .751 | .138 | |||
| PPM1D | ||||||
| n | 38 | 1849 | 9 | 519 | 29 | 1330 |
| hs-CRP GM (IQR), mg/L | 1.64 (0.67-3.43) | 1.57 (0.74-3.19) | 1.84 (0.60-5.09) | 1.59 (0.78-3.23) | 1.59 (0.74-3.28) | 1.56 (0.71-3.18) |
| Back-transformed β (95% CI)* | 0.98 (0.69-1.39) | 1.14 (0.59-2.20) | 0.95 (0.63-1.43) | |||
| % difference | −2 | 14 | −5 | |||
| P | .909 | .705 | .805 | |||
The sample size related to carriers of mutations in TP53, SF3B1, SRSF2, CBL, and JAK2 was insufficient to perform analyses in these subgroups. The presented P values are for mutations yes vs no status differences in log-transformed changes in hs-CRP.
CHIP+, carrier of mutation(s); CHIP−, noncarrier of mutation; GM, geometric mean.
Generalized linear regression model-derived ln(hs-CRP) with adjustment for age, sex, and CAD status at baseline-adjusted where CHIP− was the referent category.